Renal transplant recipients have an increased risk of non-melanoma skin cancer (NMSC) compared to in the general population. Here, we show polygenic risk scores (PRS) calculated from genome-wide association studies (GWAS) of NMSC in a general, nontransplant setting, can predict risk of, and time to posttransplant skin cancer.
| INTRODUC TI ON
Renal transplantation is an effective therapy for end-stage kidney failure, with 1-year graft survival rates of between 89% and 91% for deceased donor grafts and graft half-life of 8.8 years in the United States.
1,2 As a result of this success, malignancy is a common transplant complication, with non-melanoma skin cancers (NMSC) accounting for 95% of posttransplant malignancies.
3
Renal transplant recipients have an estimated prevalence of NMSC ranging from 2% to 18% 4 and an approximate 16-fold excess risk of developing basal cell carcinoma (BCC), and 65-fold increased risk of developing squamous cell carcinoma (SCC) relative to age-matched nontransplanted individuals. 5 A number of studies have evaluated clinical predictors of NMSC posttransplant [6] [7] [8] and robust predictors include age, sex, and type of immunosuppressive treatment. 6, 8, 9 The immunosuppressive regime chosen for a patient can have a dramatic effect on their risk of developing skin cancer, as immunosuppressants can impair the immune system's ability to scan for potentially oncogenic cells. Certain classes of immunosuppressant drugs have additional carcinogenic properties beyond their effects on the immune system. 9 For example, it has been suggested that azathioprine exposure when combined with UV light induces DNA damage, which can lead to tumorigenesis. 9 Conversely, mammalian target of rapamycin (mTOR) inhibitors, which is also used as an immunosuppressant in solid organ transplants, were reported to reduce skin cancer incidence posttransplant. 10 Despite the increased risk of skin cancer, only one study has tested for germline genetic associations with skin cancer posttransplant on a genomic scale. 7 Studying SCC in a kidney and heart transplant population, the authors highlighted increased age and azathioprine exposure as risk factors for skin cancer, but no genomewide significant genetic predictors were detected. 7 This study had limited power (n = 388) compared to genome-wide association studies (GWAS) of SCC and BCC in nontransplant populations (n = 8058+)
where robust genetic risk factors for NMSC were identified. [11] [12] [13] [14] The genetic architecture of NMSC in a transplant setting would appear to mirror that of complex human traits generally, where common genetic variants individually tend to have small effect sizes and limited clinical relevance, with some notable exceptions. 15, 16 However, by combining effect sizes across variants one can create an overall "polygenic risk score" (PRS) 17 which might produce a more clinically relevant measure of genetic load for a given trait. For the purpose of this study, PRS was defined as the sum of all alleles associated with a trait weighted by the effect size of that allele as determined by a previous GWAS.
Here we set out to leverage large, robust published GWAS to develop a PRS of NMSC and test for ability to predict in a transplant setting, case:control status and time to developing NMSC.
| MATERIAL S AND ME THODS
Written informed consent was obtained from each participant in the study. Approval for ethics study protocols was received from appropriate review committees.
| Cohort
Data on post-kidney transplant recipients were collected from 
| Genotyping, imputation, and data quality control
Belfast and Glasgow samples were genotyped using the Illumina660 K array as a part of the UK and Ireland Renal Transplant Consortium (ukirtc.org) and the Wellcome Trust Case Control Consortium 3
Study into Renal Transplant Dysfunction. 18 Genotyping details for the Dublin and Tennessee cohorts were described previously. 7, 19 Tennessee, Dublin, and Glasgow datasets were imputed using IMPUTE2 and the 1000 Genomes Phase 3 (1KG3) and Genomes of the Netherlands version 5 reference panels as previously described. [20] [21] [22] [23] [24] The Belfast dataset was phased and imputed via the Sanger Imputation Service using Eagle, PBWT, and 1KG3-reference panel. [25] [26] [27] [28] SNP2HLA and the Type 1 Diabetes Genetic Consortium were used to impute HLA alleles for each cohort. 29, 30 Imputed genotype probabilities were converted to hard-called genotypes using PLINK. 31 Calls with uncertainty greater than 0.05
were excluded using the hard-call threshold function. Variants with missingness >5%, info scores <0.95, minor allele frequency <0.05, and Hardy-Weinberg P < 1 × 10 −6 were removed. PCA was performed using GCTA to identify population outliers 32 and to control for population structure. PC (principal component) 1 and 2
were plotted using ggplot2 in R and outliers were identified. 33 To identify non-European-descent individuals, each of the datasets was merged with the Human Genome Diversity Project (HGDP) dataset 34 and PCs were calculated and plotted. Individuals that did not plot to the same region as the HGDP European groups were removed.
| Polygenic risk scores
PRS was defined as the sum of all alleles associated with a trait weighted by the effect size of that allele as determined by a previous GWAS. ) were extracted from the discovery GWAS results data from two previously published GWAS papers, one of SCC 13 and one of BCC, both in a nontransplant population. 14 The full set of discovery SNPs and associated effect sizes needed for calculating the PRS can be accessed via 23andMe. More details on accessing this data are available elsewhere. 13, 14 Effect sizes for the SNPs that reached the given pT, along with the effect allele and associated rsID were extracted from these results. These SNP sets (one for each pT) were then extracted from the transplanted cohorts' genotype data using PLINK's extract function. The genotype data was then pruned to remove SNPs in high linkage disequilibrium using PLINK with a 1000 kb sliding window, 200 kb step size, and r 2 threshold of 0.25. 31 SCC PRS, and BCC PRS were then calculated for each individual in our transplant cohorts using PLINK's score function. In each cohort, PRSs were normalized to mean zero and standard deviation of one.
| Statistical analyses
To evaluate the PRSs' predictive value, they were tested as predictors of case: control status using logistic regression, and time to developing posttransplant NMSC using Cox proportional hazards models. Covariates included age at time of transplantation, era of transplant, site, and the first eight PCs. Site was just included as a covariate for the Dublin-Glasgow analyses to account for the differences in obtaining NMSC status between the hospitals. Logistic regression was carried out using the glm function in R and Cox analysis was completed using the coxph function of the R survival package. 35, 36 To correct for multiple testing, we applied an approximate adjusted correction technique. 37 As the PRSs include subsets of the same overall group of SNPs, they are correlated. Bonferroni correction assumes tests are independent and therefore would be overly conservative. In this context, the following equation was
where
PRSs tested × number of phenotypes tested, p(k) = unadjusted Pvalue for the given PRS score, r(.k) = mean correlation among the outcomes other than outcome k.
After the P-values were adjusted for the number of PRSs tested using the above technique, further correction was applied to account for the three phenotypes being tested (NMSC, SCC, and BCC) using Bonferroni correction.
Beta coefficients were meta-analyzed using the metafor R package. 38 The percentage of variation across the results from the different sites in the meta-analysis was accessed for heterogeneity using the I 2 statistic. 39 Receiver operator curves were calculated using the pROC package in R. 40 We performed decile analysis using the most significant PRS from the NMSC logistic regression (BCC pT1 × 10 −5 ) and Cox analysis (SCC pT1 × 10 −5 ). We merged the four datasets and divided samples into decile groups with the lowest polygenic load in the first decile and the highest PRS in the tenth decile. Samples in each decile group were then compared to patients from the first decile group and tested for association with NMSC using the previously described Cox and logistic regression analysis.
| RE SULTS
Polygenic risk analysis was performed on 889 transplant recipients (567 males and 322 females), 239 of whom developed any NMSC with 106 developing BCC and 150 developing SCC (see Table 1) screened for European ancestry. Average time to developing NMSC was 2837 days with a range from 91 to 7343 days. In the total dataset, patients had a mean age of 47. In order to facilitate a comprehensive assessment of PRSs on posttransplant NMSC we first set out to identify the clinical variables influencing NMSC status in a posttransplant setting. In this context, we analyzed age at time of transplantation, sex, era of transplant, and azathioprine exposure using a logistic regression and Cox regression approach (see Section 2). These were tested against NMSC, as well as the two main subtypes of NMSC: BCC and SCC to evaluate subtype specific differences. Age alone was found to be a significant predictor of NMSC, BCC, and SCC in both the Cox and logistic regression analyses (see Table 2 ) and was brought forward as a covariate in our analyses. Although era of transplantation was not a significant predictor of skin cancer, we felt it was appropriate to include it as a covariate as to account for differences in immunosuppression regimens which are known to influence the onset of NMSC posttransplant.
41
To investigate the impact of PRS on time to NMSC, we carried out a Cox proportional hazards analysis adjusting for age, era, eight control status of NMSC, BCC, and SCC posttransplant (see Table 3 ). with 69% of the SNPs in the SCC PRS found in the BCC PRS at this threshold (see Tables S1 and S2 for SNPs used for these scores). This overlap is consistent with our finding that both SCC and BCC PRSs were significantly associated with of time to and case:control status of NMSC. Figure 1 illustrates how an increase in SCC pT1 × 10 −5 PRS leads to a faster time to developing NMSC. This effect was consistent across cohorts and the same trend was seen in the BCC and SCC subanalyses (see Table 3 ). Increased BCC pT1 × 10 −5 PRS correlated with an increased risk of developing NMSC within the first 10 years posttransplant (see Table 3 ). The aforementioned most significant results all had an I 2 of 0% indicating there was low heterogeneity across the variation of results at the different sites.
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TA B L E 1 Summary statistics of total dataset
TA B L E 2 Clinical meta-analysis results
Logistic
For the most significant PRS in the Cox and logistic NMSC analysis, we performed a decile analysis whereby samples in each decile group were compared to patients from the first (lowest) decile group and tested for association with NMSC (see Table 4 ). For this and for the proceeding receiver operator curve and concordance analyses we merged the three cohorts prior to analyzing association with NMSC. We found that for all but one of the decile groups, the lower PRS subset associated with lower risk of NMSC posttransplant and reduced time to NMSC posttransplant, with the highest polygenic load (tenth decile) group having a hazard ratio of 3.11 when compared to the first decile group.
To access the potential clinical applicability of the significant PRSs previously described, we performed a comparative receiver operator curve analysis that determined the area under the curves for the different predictive models (see Figure 2) . The most predictive model was the full model, which included age, site, era, BCC pT1 × 10 −5 PRS, and PCs.
The area under the curve for the clinical model (which included "age,"
"era," and "site") was 0.786 compared with 0.813 for the full model (which included "age," "era," "site," "PRS," and "PCs") indicating that the 
| D ISCUSS I ON
Our findings show a significant association between polygenic effects of variants associated with NMSC in the general population Samples in each decile group were compared to those in the first decile group (lowest PRS group). Analyses were adjusted for age, era of transplantation, geographic site and eight PCs. SCC, squamous cell carcinoma; BCC, basal cell carcinoma; Top PRS, most significant polygenic risk score associated with given skin cancer in given model; pT, P-value threshold; OR, odds ratio; HR, hazards ratio; Lower/Upper CI, lower/upper 95% confidence interval; P, P value; N, number of individuals tested; N events, number of skin cancer events observed; N cases, number of individuals with non-melanoma skin cancer.
TA B L E 3 PRS logistic and Cox regression top results
Logistic
Cancer type
patient on a specific treatment regime. For example, switching patients to sirolimus has been demonstrated to reduce risk of posttransplant skin cancer. 44 The knowledge of a patient's polygenic risk of skin cancer posttransplant could also inform less drastic interventions such as frequency of checks with dermatologists and may also increase a patient's likelihood to take on board lifestyle interventions such as wearing sunscreen and carrying out regular skin checks. This being said, although highly significant, the effect size of the PRS found in this study is relatively small and therefore only those in the top deciles of the distribution of polygenic burden (see Table 4 ) could realistically benefit from interventions based on their PRS. However, this study is the first of its kind to look at GWAS based PRS in a transplant setting and is proof of concept of the po- Secondly, we cannot tell if the effect of PRS on skin cancer detected here is different from that expected within a nontransplant population. It is possible the predictive value we see in this transplant population is identifying those individuals at high risk of skin cancer regardless of setting. In this context, the study was limited by the lack of a nonscreened population to test for difference in the effect size of PRS, across transplant and nontransplant populations.
For this reason, we cannot say whether this effect is specific to posttransplant NMSC or applicable to NMSC in general nor can we determine if the effect is immunosuppression related. Further, work will be required to answer this important question.
Finally, this study was done on a homogenous European population and so further work is required to assess the predictive ability of this risk score in other more diverse, non-European populations.
The alleles used to calculate the PRS were taken from two European GWA studies. For accurate interpretation of polygenic risk of NMSC in non-European populations a GWAS ethnically matched to the population being studied should be used to select alleles.
47
In conclusion, we have illustrated that PRS can be used to predict case:control status of, and time to NMSC from the time of transplantation. We found that the PRS provides limited, but significant
predictive value beyond what clinical variables alone can explain. As transplant populations are exposed to immunosuppression, surgery and, in most cases, long-term chronic disease, common genetic variants that have small effects in the general population may have increased effects in these screened populations. Therefore, the utility of PRS in transplant settings could be a useful tool both clinically and for discovery of new biological mechanisms involved in transplant outcomes.
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